CORONA Remedies Limited

Aberdeen purchased 4,50,868 shares of Corona Remedies Limited for ₹78.00 Cr at ₹1730.00 apiece through a block deal.

Corona Remedies Limited, founded in 2004 and headquartered in Ahmedabad, is a pharmaceutical company manufacturing and distributing medicines across women's healthcare, cardiology, pain management, and urology. The company operates two manufacturing facilities in Gujarat and Himachal Pradesh, holds EU-GMP and WHO certifications, and maintains market leadership positions in multiple therapeutic segments including rank #5 in women's healthcare and pain management.

Edinburgh-based global asset manager, known as abrdn until 2025 and as Standard Life Aberdeen before that. Runs active long-only Asia Pacific and India equity strategies, with a long-standing tilt toward smaller companies. Its India positions are usually built by several of its funds at the same time rather than by a single vehicle.